We turn now to a potential game changer for some 5 million Americans, who suffer from congestive heart failure. News of an experimental drug so successful, that they stopped the study early finding... See More
We turn now to a potential game changer for some 5 million Americans, who suffer from congestive heart failure. News of an experimental drug so successful, that they stopped the study early finding the drug reduced the risk of death and hospitalizations due to heart failure by 20%. ABC's senior medical contributor Dr. Jennifer Ashton is here. Jen, 20%. That is sizable. What makes this a breakthrough? It's a combination of two drugs, that really target the root cause of the problems that plague patients with heart failure. Which is namely fluid overload. It kind of works like a one two punch against the hormonal domino effect. All over the body as well as the heart muscle function better. This study saves lives and improved quality of life all with acceptable side effects. If this drug is approved, it would be the first new oral medication for heart failure in almost a decade. There are caveats, you want people to know. Absolutely. First of all the study was funded by the maker of the medication. It needs more study in african-american patients who are disproportionately affected by heart failure. Experts are still calling this a break through. But it comes with a hefty price tag it could be as much as $7 a day.
This transcript has been automatically generated and may not be 100% accurate.